Online citations, reference lists, and bibliographies.

Drug-eluting Stents For Coronary Artery Disease: A Review.

David Mingot Martín, Fergal Boyle
Published 2011 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Over the past decade the introduction of drug-eluting stents (DESs) has revolutionised the treatment of coronary artery disease. However, in recent years concern has arisen over the long-term safety and efficacy of DESs due to the occurrence of late adverse clinical events such as stent thrombosis. With this concern in mind, research and development is currently centred on increasing the long-term safety and efficacy of DESs. The aim of this paper is to provide a thorough review of currently approved and promising investigational DESs. With dozens of companies involved in the development of new and innovative anti-restenotic agents, polymeric coatings and stent platforms, it is intended that this review paper will provide a clear indication of how DESs are currently evolving and prove a valuable reference tool for future research in this area.
This paper references
A randomised comarison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study. EuroIntervention 2010;6:195–205
P Serruys (2010)
10.1016/j.jacc.2004.10.062
A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial.
J J Goy (2005)
parison of a polymer - based paclitaxel - eluting stent with a bare metal stent in patients with complex coronary artery disease : a randomized controlled trial
GW Stone (2005)
10.1016/S0140-6736(09)62127-9
Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial
Elvin Kedhi (2010)
10.1056/NEJMoa044372
Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.
Alban Dibra (2005)
A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION
ATRICK (2002)
TCT-429: single center, first-in-man study of the elixir novolimus eluting coronary stent system with durable polymer 24month clinical safety and efficacy results
A Abizaid (2009)
10.1016/j.jcin.2009.10.003
Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
Stephen G Ellis (2009)
10.1016/j.jacc.2005.01.048
Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry.
Jiro Aoki (2005)
10.1056/NEJMoa0804626
Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.
Patrick W. Serruys (2009)
A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial.
Patrick W. Serruys (2005)
10.1186/1475-925X-7-23
Simulation of stent deployment in a realistic human coronary artery
Frank JH Gijsen (2008)
10.1111/j.1540-8183.2008.00395.x
One-year outcomes with the Taxus Liberté stent in the real world: the Taxus Olympia registry (phase I).
Waqar Habib Ahmed (2008)
10.1161/CIRCULATIONAHA.105.562421
Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial
Manel Sabaté (2005)
10.1056/NEJMoa067484
Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.
Adnan Kastrati (2007)
10.1093/eurheartj/ehi721
Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels.
Julinda Mehilli (2006)
10.4244/EIJV4I1A11
Biodegradable-polymer-based, sirolimus-eluting Supralimus stent: 6-month angiographic and 30-month clinical follow-up results from the series I prospective study.
Sameer I Dani (2008)
10.1016/j.jcin.2008.10.013
Clinical and angiographic outcomes with sirolimus-eluting stents in total coronary occlusions: the ACROSS/TOSCA-4 (Approaches to Chronic Occlusions With Sirolimus-Eluting Stents/Total Occlusion Study of Coronary Arteries-4) trial.
David E Kandzari (2009)
10.1016/j.jacc.2005.10.045
The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial.
Henning Kelbaek (2006)
10.1161/CIRCULATIONAHA.108.826479
Safety and Efficacy of Drug-Eluting and Bare Metal Stents: Comprehensive Meta-Analysis of Randomized Trials and Observational Studies
Ajay J. Kirtane (2009)
10.1016/S0140-6736(10)60208-5
Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial
Klaus Bolding Rasmussen (2010)
10.1093/eurheartj/ehp352
Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial.
Robert A. Byrne (2009)
Outcomes of unselected recipients of sirolimus-eluting stents: the Cypher stent U.S. post-marketing surveillance registry.
Hiram G. Bezerra (2010)
10.1161/CIRCULATIONAHA.105.575977
Randomized Trial of a Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent for the Reduction of Late Lumen Loss
Julinda Mehilli (2006)
10.1001/jama.299.16.1903
Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial.
Gregg W Stone (2008)
10.1161/01.CIR.0000086926.62288.A6
Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions
Antonio Colombo (2003)
10.1161/ATVBAHA.107.144220
Vascular Responses to Drug Eluting Stents: Importance of Delayed Healing
Aloke V. Finn (2007)
Direct stenting with the TAXUS Liberte drug-eluting stent: results from the Please cite this article in press
JA Ormiston (2010)
10.1016/S0140-6736(09)60325-1
A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods
Patrick W. Serruys (2009)
10.1016/j.jvs.2004.02.012
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease
Gregg W Stone (2004)
10.1001/jama.299.4.409
Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial.
Anders M Galløe (2008)
TAXUS PERSEUS: a novel platinum chromium, thin-strut TAXUS Element stent for the treatment of de novo coronary stenoses
DJ Kereiakes (2010)
10.1001/jama.293.17.2109
Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.
Marco Valgimigli (2005)
10.1016/S0140-6736(07)60853-8
Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial
R. Erbel (2007)
First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial.
Ian T. Meredith (2005)
The REVA Tyrosine-derived polycarbonate bioabsorbable stent: final results from the RESORB First-in-man clinical trial and next generation
R. Grube (2008)
10.1016/j.jacc.2006.10.026
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
Matthias Emil Pfisterer (2006)
The XIENCE V-PROMUS everolimus-eluting stent: comprehensive update of the clinical trial program
GW Stone (2009)
The REVA Tyrosine-derived polycarbonate bioabsorbable stent: lessons learned and future directions
A. Abizaid (2008)
BioFreedom, first-in-man progress report: 4-month cohort followup
E. Grube (2009)
10.1016/j.amjcard.2006.06.047
Safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: the SIRIUS 2.25 trial.
Jeffrey W. Moses (2006)
10.1001/jama.292.22.2727
Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial.
Diego Ardissino (2004)
10.1056/NEJMoa0910496
Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.
Gregg W Stone (2010)
Heart disease and stroke statistics —
D Lloyd-Jones (2009)
10.1016/j.jacc.2006.08.035
Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial.
David E Kandzari (2006)
The ENDEAVOR and ENDEAVOR Resolute zotarolimus-eluting stent: comprehensive update of the clinical trial program
MB Leon (2009)
ENDEAVOR III: 5 year final outcomes
DE Kandzari (2010)
10.1161/CIRCULATIONAHA.105.591206
Randomized, Double-Blind, Multicenter Study of the Endeavor Zotarolimus-Eluting Phosphorylcholine-Encapsulated Stent for Treatment of Native Coronary Artery Lesions: Clinical and Angiographic Results of the ENDEAVOR II Trial
Jean Fajadet (2007)
Safety of coronary Sirolimuseluting stents in daily clinical practice : one - year follow - up of the eCypher registry
P Urban (2009)
10.7326/0003-4819-148-3-200802050-00199
Balancing Efficacy and Safety of Drug-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention
Allen Jeremias (2008)
10.1016/j.jacc.2009.01.050
Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial.
Giora Weisz (2009)
10.1016/S0140-6736(07)61444-5
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis
Christoph Stettler (2007)
10.1016/S0735-1097(02)02597-4
Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials.
Donald E. Cutlip (2002)
10.1016/j.jcin.2008.09.007
Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberté stent: 1-year results from the TAXUS ATLAS program.
Mark A. Turco (2008)
10.1016/j.ahj.2006.02.025
Sirolimus-eluting coronary stents in small vessels.
Bernhard Meier (2006)
10.1161/01.CIR.103.23.2816
[Intracoronary Stenting and Angiographic Results Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial].
Adnan Kastrati (2001)
10.1056/NEJMoa1004130
Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.
Patrick W. Serruys (2010)
Sirolimuseluting stent versus paclitaxel-eluting sent for patients with long coronary artery disease
Kim Y-H (2006)
10.1016/s1062-1458(01)00317-8
Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries: A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study
Jose Eduardo M. Sousa (2001)
10.1056/NEJMoa035071
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.
Jeffrey W. Moses (2003)
10.1161/CIRCULATIONAHA.107.693739
Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization
Aloke V. Finn (2007)
10.3109/9780203640265
Handbook of Drug-Eluting Stents
Patrick Wjc Serruys (2005)
10.1093/eurheartj/ehn253
Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis.
Julinda Mehilli (2008)
10.1016/j.jacc.2006.09.021
Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.
Paul Vermeersch (2006)
10.1161/CIRCULATIONAHA.104.532242
Safety of Coronary Sirolimus-Eluting Stents in Daily Clinical Practice: One-Year Follow-Up of the e-Cypher Registry
Philip M Urban (2006)
10.1161/CIRCINTERVENTIONS.109.852178.109.852178
Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries.
J. M. Lasala (2009)
10.1056/NEJM199408253310802
A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.
David L Fischman (1994)
10.1016/j.jcin.2008.01.003
Direct stenting with the TAXUS Liberté drug-eluting stent: results from the Taxus Atlas Direct Stent Study.
John A Ormiston (2008)
10.1161/CIRCULATIONAHA.108.191261
Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
Donald Lloyd-Jones (2009)
10.1016/J.JBIOMECH.2007.08.014
Realistic finite element-based stent design: the impact of balloon folding.
Matthieu De Beule (2008)
Direct stenting with the TAXUS Liberte drug-eluting stent: results from the Please cite this article in press
JA Ormiston (2010)
10.4244/EIJV4I1A10
EXCELLA First-in-Man (FIM) study: safety and efficacy of novolimus-eluting stent in de novo coronary lesions.
J Ribamar Costa (2008)
10.1056/NEJMoa062006
Sirolimus-eluting versus uncoated stents in acute myocardial infarction.
Christian Spaulding (2006)
10.1093/eurheartj/ehp476
Genous™ endothelial progenitor cell capturing stent vs. the Taxus Liberté stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study
Marcel A.M. Beijk (2010)
10.1016/j.amjcard.2006.05.020
Twelve-month outcomes with a paclitaxel-eluting stent transitioning from controlled trials to clinical practice (the WISDOM Registry).
Alexandre Antônio Cunha Abizaid (2006)
10.1016/J.JACC.2007.07.035
One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients.
D. Baumgart (2007)
10.1016/j.amjcard.2008.03.055
Observations and outcomes of definite and probable drug-eluting stent thrombosis seen at a single hospital in a four-year period.
Tina L. Pinto Slottow (2008)
10.1001/jama.293.17.2126
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.
Ioannis Iakovou (2005)
10.1038/305163a0
Cause for concern
Eric Ashby (1983)
parison of a polymerbased paclitaxeleluting stent with a bare metal stent in patients with complex coronary artery disease : a randomized controlled trial
GW Stone (2005)
10.4244/EIJV6I2A32
A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study.
Patrick W. Serruys (2010)
10.1161/01.CIR.0000109138.84579.FA
Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the “Real World”: The R apamycin-E luting S tent E valuated A t R otterdam C ardiology H ospital (RESEARCH) Registry
Pedro Alves Lemos (2004)
first-in-man progress report: 4-month cohort followup
Grube E Biofreedom (2009)
10.1016/S0140-6736(07)60314-6
Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study
Joost Daemen (2007)
10.1093/eurheartj/ehl282
Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis.
Alain J. Nordmann (2006)
10.1002/ccd.22428
Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
Marcus Wiemer (2010)
10.1016/j.jacc.2005.10.078
A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial.
Fernando Alfonso (2006)
10.1161/CIRCULATIONAHA.107.762047
Delayed Arterial Healing and Increased Late Stent Thrombosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction Patients: An Autopsy Study
Gaku Nakazawa (2008)
10.1016/S0021-9290(06)84629-4
Fluid mechanical perturbations induced by stent implantation: a numerical study
Rossella Balossino (2006)
The REVA Tyrosine - derived polycarbonate bioabsorbable stent : final results from the RESORB First - inman clinical trial and next generation designs
R Grube (2008)
Direct stenting with the TAXUS Liberte drug-eluting stent: results from the G Model JJBE-1778
J A Ormiston
10.1016/j.jacc.2007.06.047
A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.
Albert Schoemig (2007)
LEADERS: two-year follow-up from a prospective randomised trial of biolimus A9-eluting stents with a bioabsorbable polymer vs. sirolimuseluting stents with a durable polymer
V. Klauss (2009)
10.1161/01.CIR.0000148371.53174.05
Nonuniform Strut Distribution Correlates With More Neointimal Hyperplasia After Sirolimus-Eluting Stent Implantation
Hideo Takebayashi (2004)
10.1016/j.jacc.2008.07.006
Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study.
Peter Wenaweser (2008)
10.1016/j.jacc.2007.09.056
Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study.
Bas L van der Hoeven (2008)
Poly-anhydride based on salicylic acid and adipic acid anhydride
R. Jabara (2009)
Drugeluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries. Circ: Cardiovasc Intervent 2009;2:285–93
JM Lasala (2009)
10.1161/CIRCINTERVENTIONS.108.823443
Randomized Comparison of the Nobori Biolimus A9-Eluting Coronary Stent With the Taxus Liberté Paclitaxel-Eluting Coronary Stent in Patients With Stenosis in Native Coronary Arteries: The NOBORI 1 Trial—Phase 2
Bernard Chevalier (2009)
10.4244/EIJV2I4A78
Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus(R), paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial.
Bernard Chevalier (2007)
10.1016/j.cma.2008.07.019
Numerical simulation of drug eluting coronary stents: Mechanics, fluid dynamics and drug release
Paolo Zunino (2009)
10.1161/CIRCULATIONAHA.108.191259
Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
Donald Lloyd‐Jones (2009)
10.1016/j.jcin.2009.07.007
Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial.
Ian T. Meredith (2009)
10.4244/
A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study.
Patrick W. Serruys (2010)
10.1056/NEJMoa066633
A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents.
Christian Spaulding (2007)
Endeavor + Resolute: preclinical foundation and clinical results
MB Leon (2010)
Safety of coronary Sirolimus-eluting stents in daily clinical practice: one-year followup of the e-Cypher registry. Circulation 2006;113:1434–41
P Urban (2006)
10.1161/CIRCULATIONAHA.106.666396
Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent for Patients With Long Coronary Artery Disease
Young-Hak Kim (2006)
10.1016/j.jacc.2008.01.020
A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
Mitchell W. Krucoff (2008)
10.1161/CIRCULATIONAHA.106.613588
Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): A Randomized Comparison of Bare Metal Stent Implantation With Sirolimus-Eluting Stent Implantation for the Treatment of Total Coronary Occlusions
Maarten Jan Suttorp (2006)
10.4244/EIJV3I3A64
Accelerated vascular repair following percutaneous coronary intervention by capture of endothelial progenitor cells promotes regression of neointimal growth at long term follow-up: final results of the Healing II trial using an endothelial progenitor cell capturing stent (Genous R stent).
Henricus J. Duckers (2007)
Final angiographic and IVUS results of the ZEST trial
CW Lee (2009)
Sirolimuseluting versus uncoated stents in acute myocardial infarction
C Spaulding (2006)
10.1016/j.accreview.2005.02.086
Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial.
Adnan Kastrati (2005)
10.4244/EIJV2I3A56
Biodegradable-polymer-based, paclitaxel-eluting Infinnium stent: 9-Month clinical and angiographic follow-up results from the SIMPLE II prospective multi-centre registry study.
Pascal Vranckx (2006)
10.1161/CIRCULATIONAHA.106.621714
Mobilization of CD34-Positive Bone Marrow–Derived Cells After Coronary Stent Implantation: Impact on Restenosis
Teruo Inoue (2007)
10.1016/j.jacc.2006.03.042
Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.
Michael D. Joner (2006)
10.1161/CIRCINTERVENTIONS.109.919936
Development of a Novel Prohealing Stent Designed to Deliver Sirolimus From a Biodegradable Abluminal Matrix
Juan F Granada (2010)
Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind
J Schofer (2003)
10.1016/j.jacc.2007.01.069
Polymer-based, paclitaxel-eluting TAXUS Liberté stent in de novo lesions: the pivotal TAXUS ATLAS trial.
Mark A. Turco (2007)
10.4244/EIJ30V6I4A76
Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial.
Yosinobu Onuma (2010)
10.1001/jama.295.8.895
Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.
M Morice (2006)
10.1016/j.jacc.2009.05.016
The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry.
Yoshinobu Onuma (2009)
10.1016/S0140-6736(03)14462-5
Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS)
Joachim J Schofer (2003)
10.1016/j.amjcard.2006.02.039
Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up.
Duk-Woo Park (2006)
10.1016/j.jacc.2004.01.024
The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS).
Erick Schampaert (2004)
10.1016/j.jacc.2005.01.008
The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry.
Andrew T.L. Ong (2005)
10.4244/EIJV1I1A06
Six-month results of a randomized study to evaluate safety and efficacy of a Biolimus A9 eluting stent with a biodegradable polymer coating.
Eberhard Grube (2005)
10.1016/j.amjcard.2007.08.026
Real-world safety and efficacy of the endeavor zotarolimus-eluting stent: early data from the E-Five Registry.
Ajay Kumar Jain (2007)
update : a report from the American Heart Association statistics committee and stroke statistics sub - committee
DL Fischman
10.1016/j.jacc.2007.01.081
Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI).
Maurizio Menichelli (2007)
10.1016/j.jacc.2009.08.067
A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial.
M. Bonilla León (2010)
10.1016/S0140-6736(08)61244-1
Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial
Stephan W Windecker (2008)
10.1161/01.CIR.0000047700.58683.A1
TAXUS I: Six- and Twelve-Month Results From a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions
Eberhard Grube (2003)
10.1056/NEJMoa067722
Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.
Bo Lagerqvist (2007)
10.1016/S0735-1097(03)00119-0
Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial
Adnan Kastrati (2001)
The REVA Tyrosinederived polycarbonate bioabsorbable stent : final results from the RESORB Firstinman clinical trial and next generation designs
R Grube (2008)
10.1161/01.CIR.103.2.192
Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study
Jose Eduardo M. Sousa (2001)
10.1161/CIRCULATIONAHA.105.552190
Clinical Efficacy of Polymer-Based Paclitaxel-Eluting Stents in the Treatment of Complex, Long Coronary Artery Lesions From a Multicenter, Randomized Trial: Support for the Use of Drug-Eluting Stents in Contemporary Clinical Practice
Keith D. Dawkins (2005)
10.4244/EIJV2I3A53
A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial.
Patrick W. Serruys (2006)
10.1056/NEJMoa067193
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
Gregg W Stone (2007)
10.1056/NEJMoa051175
Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization.
Stephan W Windecker (2005)
10.4244/EIJV2I1A09
Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbostents. The randomized JUPITER II trial.
M Morice (2006)
Randomised comparison of Genous stent versus chromium-cobalt stent for treatment of ST-elevated myocardial infarction. 6-Month clinical, angiographic and IVUS follow-up
P Cervinka (2009)
10.1016/j.accreview.2005.11.049
Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial.
Gregg W Stone (2005)
10.1016/j.jacc.2008.04.030
Endothelial cell recovery between comparator polymer-based drug-eluting stents.
Michael D. Joner (2008)
10.1016/S0140-6736(08)60415-8
A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial
John A Ormiston (2008)



This paper is referenced by
10.1039/C5TB01313E
Proliferation and functionality of human umbilical vein endothelial cells on angiopoietin-1 immobilized 316L stainless steel.
Xin Li (2015)
10.1177/0883911512465699
Bioactive coatings for coronary stents: Modulation of cell proliferation by controlled release of anti-proliferative drugs
Gema María Gómez Rodríguez (2012)
10.21427/D7G31Z
Sequential Structural and Fluid Dynamics Analysis of Balloon-Expandable Coronary Stents.
David D Martin (2013)
Simulation of heparin distribution in an injured coronary artery
Seyed Masoud Vahedi (2016)
10.1115/SBC2012-80045
Flow in the Vascular System Post Stent Implantation: Examining the Near-Stent Flow Physics
Chekema Prince (2012)
10.1016/J.SURFCOAT.2013.02.008
Surface modification of cardiovascular materials and implants
Pengkai Qi (2013)
10.1016/j.jpba.2012.05.038
UV-visible spectroscopy as an alternative to liquid chromatography for determination of everolimus in surfactant-containing dissolution media: a useful approach based on solid-phase extraction.
Marika Kamberi (2012)
10.1002/jbm.a.35339
Tailoring of the dopamine coated surface with VEGF loaded heparin/poly-L-lysine particles for anticoagulation and accelerate in situ endothelialization.
Yang Liu (2015)
Construction of Nano-Assembled Microcapsules Embedded with Gold Nanoparticles for use in Novel Drug Delivery Systems
Abraham Samuel Finny (2016)
10.32640/tasj.2020.1.38
Study of mechanical behavior of additive manufacturing bioresorbable polymeric stents models
Adriana Del Monaco (2020)
Fabrication and Evaluation of Multiple Memory Nitinol Stents for Biomedical Applications
Gitanjali Shanbhag (2017)
10.2217/ICA.11.88
Drug-eluting stent coatings
X Ma (2012)
10.1002/9781119580546.ch12
Polymer and Carbon-Based Coatings for Biomedical Applications
S. J. Owonubi (2019)
10.3390/ph10010023
RNA-Eluting Surfaces for the Modulation of Gene Expression as A Novel Stent Concept
Olivia Koenig (2017)
10.1016/j.jbiomech.2014.07.030
Numerical investigations of the haemodynamic changes associated with stent malapposition in an idealised coronary artery.
Eric K. W. Poon (2014)
Multi-objective optimization of laser milling parameters of micro-cavities for the manufacturing of DES
Daniel Teixidor (2014)
10.1371/journal.pone.0151259
Can Platforms Affect the Safety and Efficacy of Drug-Eluting Stents in the Era of Biodegradable Polymers?: A Meta-Analysis of 34,850 Randomized Individuals
Yunfeng Yan (2016)
10.12968/BJCA.2018.13.5.229
Coronary artery stents: part 2
Nazish Khan (2018)
10.1016/j.ccl.2016.12.010
Contemporary Drug-Eluting Stent Platforms: Design, Safety, and Clinical Efficacy.
Ramon A. Partida (2017)
10.1039/C5RA19109B
The metamorphosis of vascular stents: passive structures to smart devices
Purandhi Roopmani (2016)
10.1021/acsami.5b01993
Controlled Slow-Release Drug-Eluting Stents for the Prevention of Coronary Restenosis: Recent Progress and Future Prospects.
Tingzhang Hu (2015)
10.1016/J.REACTFUNCTPOLYM.2013.03.019
Novel Poly(3-hydroxyoctanoate)/Poly(3-hydroxybutyrate) blends for medical applications
Pooja Basnett (2013)
10.1016/J.CEJ.2019.122116
Heparin coating on 3D printed poly (l-lactic acid) biodegradable cardiovascular stent via mild surface modification approach for coronary artery implantation
Seung Joon Lee (2019)
10.1016/j.jmbbm.2019.103610
How does stent expansion alter drug transport properties of the arterial wall?
Javier Escuer (2020)
10.1016/J.PROGPOLYMSCI.2018.07.005
Pharmapolymers in the 21st century: Synthetic polymers in drug delivery applications
Christoph Englert (2018)
10.17925/hi.2019.13.2.17
A Review of the Ultrathin Orsiro Biodegradable Polymer Drug-eluting Stent in the Treatment of Coronary Artery Disease
James J. Wu (2019)
10.7439/IJBAR.V4I11.560
An Evolutionary Appraisal of the Efficacy of Coronary Artery Stents relevant to the Treatment of Coronary Heart Diseases
Faisal Amin (2013)
10.1586/14779072.2013.837694
Long-term safety of drug-eluting stents
Florian N Riede (2013)
10.4244/EIJV8I9A156
First-in-man evaluation of the MOMO cobalt-chromium carbon-coated stent.
Sujatha Kesavan (2013)
10.1002/wnan.1236
Fabricated micro-nano devices for in vivo and in vitro biomedical applications.
Swetha Barkam (2013)
10.1007/S11434-013-6070-1
Current status of research and application in vascular stents
Pengkai Qi (2013)
10.1016/j.ijpharm.2017.12.007
Modelling drug release from polymer‐free coronary stents with microporous surfaces
Tuoi T. N. Vo (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar